Cargando…
The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer
Given their tumor-specific and stage-specific gene expression, long non-coding RNAs (lncRNAs) have demonstrated to be potential molecular biomarkers for diagnosis, prognosis, and treatment response. Particularly, the lncRNAs DSCAM-AS1 and GATA3-AS1 serve as examples of this because of their high sub...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138835/ https://www.ncbi.nlm.nih.gov/pubmed/37108589 http://dx.doi.org/10.3390/ijms24087426 |
_version_ | 1785032800943996928 |
---|---|
author | Arriaga-Canon, Cristian Contreras-Espinosa, Laura Aguilar-Villanueva, Sergio Bargalló-Rocha, Enrique García-Gordillo, José Antonio Cabrera-Galeana, Paula Castro-Hernández, Clementina Jiménez-Trejo, Francisco Herrera, L. A. |
author_facet | Arriaga-Canon, Cristian Contreras-Espinosa, Laura Aguilar-Villanueva, Sergio Bargalló-Rocha, Enrique García-Gordillo, José Antonio Cabrera-Galeana, Paula Castro-Hernández, Clementina Jiménez-Trejo, Francisco Herrera, L. A. |
author_sort | Arriaga-Canon, Cristian |
collection | PubMed |
description | Given their tumor-specific and stage-specific gene expression, long non-coding RNAs (lncRNAs) have demonstrated to be potential molecular biomarkers for diagnosis, prognosis, and treatment response. Particularly, the lncRNAs DSCAM-AS1 and GATA3-AS1 serve as examples of this because of their high subtype-specific expression profile in luminal B-like breast cancer. This makes them candidates to use as molecular biomarkers in clinical practice. However, lncRNA studies in breast cancer are limited in sample size and are restricted to the determination of their biological function, which represents an obstacle for its inclusion as molecular biomarkers of clinical utility. Nevertheless, due to their expression specificity among diseases, such as cancer, and their stability in body fluids, lncRNAs are promising molecular biomarkers that could improve the reliability, sensitivity, and specificity of molecular techniques used in clinical diagnosis. The development of lncRNA-based diagnostics and lncRNA-based therapeutics will be useful in routine medical practice to improve patient clinical management and quality of life. |
format | Online Article Text |
id | pubmed-10138835 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101388352023-04-28 The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer Arriaga-Canon, Cristian Contreras-Espinosa, Laura Aguilar-Villanueva, Sergio Bargalló-Rocha, Enrique García-Gordillo, José Antonio Cabrera-Galeana, Paula Castro-Hernández, Clementina Jiménez-Trejo, Francisco Herrera, L. A. Int J Mol Sci Review Given their tumor-specific and stage-specific gene expression, long non-coding RNAs (lncRNAs) have demonstrated to be potential molecular biomarkers for diagnosis, prognosis, and treatment response. Particularly, the lncRNAs DSCAM-AS1 and GATA3-AS1 serve as examples of this because of their high subtype-specific expression profile in luminal B-like breast cancer. This makes them candidates to use as molecular biomarkers in clinical practice. However, lncRNA studies in breast cancer are limited in sample size and are restricted to the determination of their biological function, which represents an obstacle for its inclusion as molecular biomarkers of clinical utility. Nevertheless, due to their expression specificity among diseases, such as cancer, and their stability in body fluids, lncRNAs are promising molecular biomarkers that could improve the reliability, sensitivity, and specificity of molecular techniques used in clinical diagnosis. The development of lncRNA-based diagnostics and lncRNA-based therapeutics will be useful in routine medical practice to improve patient clinical management and quality of life. MDPI 2023-04-18 /pmc/articles/PMC10138835/ /pubmed/37108589 http://dx.doi.org/10.3390/ijms24087426 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Arriaga-Canon, Cristian Contreras-Espinosa, Laura Aguilar-Villanueva, Sergio Bargalló-Rocha, Enrique García-Gordillo, José Antonio Cabrera-Galeana, Paula Castro-Hernández, Clementina Jiménez-Trejo, Francisco Herrera, L. A. The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer |
title | The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer |
title_full | The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer |
title_fullStr | The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer |
title_full_unstemmed | The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer |
title_short | The Clinical Utility of lncRNAs and Their Application as Molecular Biomarkers in Breast Cancer |
title_sort | clinical utility of lncrnas and their application as molecular biomarkers in breast cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138835/ https://www.ncbi.nlm.nih.gov/pubmed/37108589 http://dx.doi.org/10.3390/ijms24087426 |
work_keys_str_mv | AT arriagacanoncristian theclinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer AT contrerasespinosalaura theclinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer AT aguilarvillanuevasergio theclinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer AT bargallorochaenrique theclinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer AT garciagordillojoseantonio theclinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer AT cabreragaleanapaula theclinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer AT castrohernandezclementina theclinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer AT jimeneztrejofrancisco theclinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer AT herrerala theclinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer AT arriagacanoncristian clinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer AT contrerasespinosalaura clinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer AT aguilarvillanuevasergio clinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer AT bargallorochaenrique clinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer AT garciagordillojoseantonio clinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer AT cabreragaleanapaula clinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer AT castrohernandezclementina clinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer AT jimeneztrejofrancisco clinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer AT herrerala clinicalutilityoflncrnasandtheirapplicationasmolecularbiomarkersinbreastcancer |